KR101025226B1 - 신규한 쿠르쿠민 유사체 및 그 용도 - Google Patents

신규한 쿠르쿠민 유사체 및 그 용도 Download PDF

Info

Publication number
KR101025226B1
KR101025226B1 KR1020097018211A KR20097018211A KR101025226B1 KR 101025226 B1 KR101025226 B1 KR 101025226B1 KR 1020097018211 A KR1020097018211 A KR 1020097018211A KR 20097018211 A KR20097018211 A KR 20097018211A KR 101025226 B1 KR101025226 B1 KR 101025226B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
pharmaceutical formulation
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097018211A
Other languages
English (en)
Korean (ko)
Other versions
KR20090132590A (ko
Inventor
쿠오-시웅 리
준코 이시다
히로나리 오츠
후이-캉 왕
히데지 이토카와
차운샹 창
찰스 씨. 와이. 시
Original Assignee
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐
앤드로사이언스 코포레이션
더 유니버시티 오브 로체스터 메디컬 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐, 앤드로사이언스 코포레이션, 더 유니버시티 오브 로체스터 메디컬 센터 filed Critical 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐
Publication of KR20090132590A publication Critical patent/KR20090132590A/ko
Application granted granted Critical
Publication of KR101025226B1 publication Critical patent/KR101025226B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/17—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/172—Saturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C07C49/245—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings
    • C07C49/248—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
KR1020097018211A 2002-04-17 2003-03-27 신규한 쿠르쿠민 유사체 및 그 용도 Expired - Fee Related KR101025226B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/124,642 2002-04-17
US10/124,642 US6790979B2 (en) 2002-04-17 2002-04-17 Curcumin analogues and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020047016357A Division KR100984512B1 (ko) 2002-04-17 2003-03-27 신규한 쿠르쿠민 유사체 및 그 용도

Publications (2)

Publication Number Publication Date
KR20090132590A KR20090132590A (ko) 2009-12-30
KR101025226B1 true KR101025226B1 (ko) 2011-04-01

Family

ID=29248380

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097018211A Expired - Fee Related KR101025226B1 (ko) 2002-04-17 2003-03-27 신규한 쿠르쿠민 유사체 및 그 용도
KR1020047016357A Expired - Fee Related KR100984512B1 (ko) 2002-04-17 2003-03-27 신규한 쿠르쿠민 유사체 및 그 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020047016357A Expired - Fee Related KR100984512B1 (ko) 2002-04-17 2003-03-27 신규한 쿠르쿠민 유사체 및 그 용도

Country Status (14)

Country Link
US (1) US6790979B2 (cg-RX-API-DMAC7.html)
EP (1) EP1494993B1 (cg-RX-API-DMAC7.html)
JP (2) JP5108198B2 (cg-RX-API-DMAC7.html)
KR (2) KR101025226B1 (cg-RX-API-DMAC7.html)
CN (1) CN1646473B (cg-RX-API-DMAC7.html)
AT (1) ATE466832T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003222087B8 (cg-RX-API-DMAC7.html)
CA (1) CA2482002C (cg-RX-API-DMAC7.html)
DE (1) DE60332445D1 (cg-RX-API-DMAC7.html)
DK (1) DK1494993T3 (cg-RX-API-DMAC7.html)
ES (1) ES2345930T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04010180A (cg-RX-API-DMAC7.html)
NZ (1) NZ535773A (cg-RX-API-DMAC7.html)
WO (1) WO2003088927A2 (cg-RX-API-DMAC7.html)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355081B2 (en) * 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
WO2003105751A2 (en) * 2002-06-17 2003-12-24 Ho-Jeong Kwon Novel curcumin derivatives
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
PL1624878T3 (pl) * 2003-05-22 2007-01-31 Pantarhei Bioscience Bv Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu
US20050049299A1 (en) * 2003-08-26 2005-03-03 Aggarwal Bharat B. Selective inhibitors of stat-3 activation and uses thereof
US20080050387A1 (en) * 2003-12-12 2008-02-28 Chawnshang Chang Non-Androgen Dependent Roles for Androgen Receptor and Non-Androgen Related Inhibitors of Androgen Receptor
CA2554025A1 (en) * 2004-01-28 2005-08-11 Androscience Corporation Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1804806A2 (en) * 2004-09-02 2007-07-11 AndroScience Corporation Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
WO2006033943A2 (en) * 2004-09-17 2006-03-30 Exelixis, Inc Pyrazole kinase modulators and methods of use
FR2880276A1 (fr) * 2005-01-05 2006-07-07 Lefebvre Dominique Caparros Utilisation des anti-androgenes dans le traitement des comportements agressifs ou impulsifs induits par des maladies du systeme nerveux central
EP2023951A4 (en) * 2006-05-19 2010-01-13 Univ Rochester PROSTATEEPITHEL ANDROGEN RECEPTOR FOR THE SUPPRESSION OF PROSTATE GROWTH AND TUMORINVASION
US7507864B2 (en) * 2006-08-01 2009-03-24 Salisbury University Method for the synthesis of curcumin analogues
WO2008045534A2 (en) * 2006-10-12 2008-04-17 Research Foundation Of The City University Of New York Novel curcumin and tetrahydrocurcumin derivatives
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
DK2104659T3 (en) * 2007-01-08 2015-11-02 Allianz Pharmascience Ltd Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
CN102432447B (zh) * 2007-01-22 2014-01-08 温州医学院生物与天然药物开发中心有限公司 含环戊酮的姜黄素单羰基结构类似物及其用途
CN102381951B (zh) * 2007-01-22 2013-09-04 温州医学院生物与天然药物开发中心有限公司 含环己酮的姜黄素单羰基结构类似物及其用途
CN101003470B (zh) * 2007-01-22 2011-11-02 温州医学院生物与天然药物开发中心有限公司 姜黄素单羰基结构类似物及其用途
WO2008131059A2 (en) * 2007-04-17 2008-10-30 Codman & Shurtleff, Inc. Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease
US8383865B2 (en) * 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
CA2694953C (en) 2007-07-31 2015-12-01 Androscience Corporation Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss
CN101255119B (zh) * 2008-01-07 2014-05-21 沈阳药科大学 四氢姜黄素衍生物及盐类
US20090282496A1 (en) * 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer
CN102046575B (zh) * 2008-05-30 2014-10-29 国立大学法人东京工业大学 阿尔茨海默病治疗药
CN101434525B (zh) * 2008-06-05 2012-07-04 福建医科大学 4-(4-羟基-3-甲氧基苯甲基)姜黄素及其用于制备抗肿瘤药物的应用
US7985776B2 (en) * 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
WO2010033580A2 (en) 2008-09-19 2010-03-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Curcumin conjugates for treating and preventing cancers
US7723515B1 (en) * 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US20100286585A1 (en) * 2009-01-26 2010-11-11 Codman & Shurtleff, Inc. Shunt Delivery of Curcumin
CN101805285B (zh) * 2009-02-13 2012-02-22 南华大学 含烟酸姜黄素酯衍生物及其制造方法和用途
ES2761173T3 (es) 2009-05-15 2020-05-19 Univ New York State Res Found Análogos de curcumina como quelantes de zinc y sus usos
CN101570515B (zh) * 2009-06-12 2011-10-19 乐山师范学院 姜黄素取代嘧啶类衍生物及其制备方法与用途
CN102091060A (zh) * 2009-12-10 2011-06-15 温州医学院 治疗或预防糖皮质激素介导的性腺功能减退性功能障碍和/或不育的药物及其应用
US8575221B2 (en) 2010-03-17 2013-11-05 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
CN102126938B (zh) * 2010-12-15 2013-03-27 厦门大学 一种姜黄素类似物及其制备方法和应用
KR101952222B1 (ko) * 2011-04-11 2019-02-26 그린 테크 가부시키가이샤 신규 피라졸 유도체
EP2782643A1 (en) * 2011-11-23 2014-10-01 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Androgen receptor ligands
CN102649750B (zh) * 2012-04-11 2014-01-22 福建医科大学 姜黄素水杨酰单酯及其合成方法以及其在抗肿瘤、抗炎方面的应用
ES2775173T3 (es) * 2012-06-18 2020-07-24 Allianz Pharmascience Ltd Compuestos con armazón estructural de (1E,6E)-1,7-bis-(3,4-dimetoxifenil)-4,4-disustituido-hepa-1,6-dieno-3,5-di-ona, su actividad biológica y usos de los mismos
US9220695B2 (en) 2012-06-29 2015-12-29 The Research Foundation For The State University Of New York Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances
US20160008297A1 (en) * 2012-08-23 2016-01-14 B.R.A.I.N. Biotechnology Research And Information Network Ag Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
WO2014057772A1 (ja) 2012-10-10 2014-04-17 株式会社ファルマエイト 新規ピラゾール誘導体
CN103159644B (zh) * 2013-04-08 2015-04-15 唐山师范学院 类姜黄素缩芳香胺希夫碱衍生物及其在制备抗菌药物的应用
CN103222970B (zh) * 2013-04-10 2019-03-26 温州医科大学 不对称单羰基姜黄素类似物在制备抗肿瘤药物中的应用
CN103254051B (zh) * 2013-05-28 2015-08-12 常州大学 一种二烷基姜黄素的制备方法
JP6369751B2 (ja) * 2014-09-05 2018-08-08 二村 芳弘 ケラチン産生作用を呈するクルクミン誘導体及びその製造方法
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US9402834B2 (en) 2014-10-21 2016-08-02 Ions Pharmaceutical S.À R.L. Human therapeutic agents
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
CN104557496B (zh) * 2015-01-21 2018-03-16 温州医科大学 单羰基类化合物、组合物及在制备药物中的应用
WO2018005732A1 (en) 2016-06-29 2018-01-04 The General Hospital Corporation Half-curcuminoids as amyloid-beta pet imaging agents
US10300000B2 (en) 2016-09-12 2019-05-28 The Research Foundation For The State University Of New York Inhibition of melanogenesis by chemically modified curcumins
CN106800547B (zh) * 2017-01-03 2019-07-23 中国人民解放军第二军医大学 一种双取代芳基类化合物及其应用
EP3582747B1 (en) * 2017-02-15 2021-10-13 Unilever Global IP Limited A personal care composition
CA3062161A1 (en) 2017-05-01 2018-11-08 Spg Therapeutics, Inc. Tripartite androgen receptor eliminators, methods and uses thereof
CN111315370B (zh) * 2018-07-28 2023-09-29 苏州沪云新药研发股份有限公司 一种具有抗炎症性肠病作用的药物及其制备方法和应用
PL4045071T3 (pl) * 2019-10-15 2026-06-29 Sami-Sabinsa Group Limited Kompozycja kurkuminoidów do terpauetycznego postępowania w zespole metanolicznym
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07165724A (ja) * 1993-12-13 1995-06-27 Nkk Corp ピラゾール誘導体及び血液凝固阻害剤
IL112205A0 (en) * 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5679864A (en) * 1995-11-03 1997-10-21 Gene Print Inc. Process for the synthesis of curcumin-related compounds
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물
JP2000258904A (ja) * 1999-03-04 2000-09-22 Fujifilm Olin Co Ltd ネガ型化学増幅系感光性組成物
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
AU779230C (en) 1999-12-03 2006-05-25 Emory University Curcumin analogues for treating cancer
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
WO2004052351A1 (en) * 2002-12-06 2004-06-24 Dsm Ip Assets B.V. Novel use of lycopene
WO2004080396A2 (en) * 2003-03-07 2004-09-23 The University Of Texas Md Anderson Cancer Center Liposomal curcumin for treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anti-Cancer Drug Design(2001), 16(6) 261-270
Joournal of Labelled Compounds and Radio pharmaceuticals, 43(a), 883-889

Also Published As

Publication number Publication date
CN1646473B (zh) 2010-10-13
CN1646473A (zh) 2005-07-27
DE60332445D1 (de) 2010-06-17
KR20050009989A (ko) 2005-01-26
JP2010150266A (ja) 2010-07-08
ATE466832T1 (de) 2010-05-15
DK1494993T3 (da) 2010-08-23
WO2003088927A3 (en) 2004-04-01
NZ535773A (en) 2007-01-26
KR100984512B1 (ko) 2010-09-30
WO2003088927A2 (en) 2003-10-30
MXPA04010180A (es) 2005-02-03
US20030203933A1 (en) 2003-10-30
JP2005534626A (ja) 2005-11-17
EP1494993A2 (en) 2005-01-12
HK1078846A1 (en) 2006-03-24
AU2003222087B8 (en) 2008-09-04
KR20090132590A (ko) 2009-12-30
ES2345930T3 (es) 2010-10-06
US6790979B2 (en) 2004-09-14
CA2482002A1 (en) 2003-10-30
EP1494993B1 (en) 2010-05-05
AU2003222087B2 (en) 2008-08-21
CA2482002C (en) 2012-07-17
JP5108198B2 (ja) 2012-12-26
AU2003222087A1 (en) 2003-11-03
EP1494993A4 (en) 2005-09-14

Similar Documents

Publication Publication Date Title
KR100984512B1 (ko) 신규한 쿠르쿠민 유사체 및 그 용도
US7709535B2 (en) Curcumin analogues and uses thereof
US12162818B2 (en) Inhibitors of the n-terminal domain of the androgen receptor
US20030013762A1 (en) 6-methoxy-2-naphthylacetic acid prodrugs
CA2744360A1 (en) Hybrid -ionone and curcumin molecules as anticancer agents
AU2008243284B2 (en) Novel curcumin analogues and uses thereof
HK1078846B (en) Novel curcumin analogues and uses thereof
CA2387098A1 (en) 6-methoxy-2-naphthylacetic acid prodrugs compositions for treating inflammation
EP4665709A1 (en) Inhibitors of the n-terminal domain of the androgen receptor

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20140322

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140322

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000